A low pCR rate was observed in HR+ and HER2- patients [49]–[51], while a markedly higher pCR rate was reported in HER2+ or triple-negative breast cancer (TNBC) patients [52]–[54]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.